Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
NPC Blog
NPC Blog
2010 Archives
2009 Archives
2008 Archives
2007 Archives
2006 Archives
Search Archives
Archives
  • December 2012 (3)
  • November 2012 (1)
  • October 2012 (1)
  • May 2012 (1)
  • December 2011 (1)
  • November 2011 (3)
  • October 2011 (4)
  • September 2011 (4)
  • August 2011 (6)
  • July 2011 (13)
  • June 2011 (8)
  • May 2011 (10)
  • April 2011 (14)
  • March 2011 (6)
  • February 2011 (2)
  • February 2010 (4)
  • January 2010 (1)
  • December 2009 (1)
  • November 2009 (1)
  • October 2009 (1)
  • September 2009 (2)
  • July 2009 (1)
  • April 2009 (1)
  • March 2009 (1)
  • February 2009 (1)
  • December 2008 (1)
  • October 2008 (1)
  • September 2008 (1)
  • August 2008 (2)
  • July 2008 (2)
  • June 2008 (4)
  • May 2008 (1)
  • April 2008 (1)
  • March 2008 (4)
  • February 2008 (1)
  • April 2007 (1)
  • December 2006 (1)
  • October 2006 (1)
  • September 2006 (1)
  • July 2006 (2)
  • June 2006 (3)
  •  

    Subscribe in a reader

    E-Alerts
    Signup to receive news and announcements from Nutra Pharma:
    First Name:
    Last Name:
    Email:
     
    Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

    NPC Blog

    Archive for 2008

    2008 turned out to be an exciting and important year for completing large drug discovery milestones at Nutra Pharma.  As the year quickly comes to a close, I wanted to take a moment to reflect back on our top accomplishments… Medical Devices We began developing and marketing through our medical devices subsidiary, Designer Diagnostics, the [...]

    Read Full Post »

     

    For the past week, we have fielded several phone calls and emails asking us about the status of our clinical data for our Phase IIb study in treating Adrenomyeloneuropathy (AMN). While we are working diligently to get this information compiled, analyzed, and published as quickly as possible, it has taken a little longer than expected [...]

    Read Full Post »

     

    In 1983, the United States Congress passed legislation, known as the Orphan Drug Act, to incentivize companies to develop drugs for diseases with prevalence rates of less than 200,000 patients in the United States. Having such low prevalence rates, these diseases were defined in the Act as “rare diseases” or “orphan diseases”. Prior to the [...]

    Read Full Post »

     

    For the past several weeks, we’ve been updating our 2008 Corporate Presentation. It’s finally complete and we’re excited to share it with you. Feel free to download a copy of the Presentation by clicking on the image above or by clicking here. (Adobe Acrobat Reader is required to view this document. If you do not have Adobe [...]

    Read Full Post »

     

    Dear Fellow Shareholders of Nutra Pharma: As the Chairman, Chief Executive Officer, and fellow investor in the Company, I am excited and pleased to share with you the recent progress we have made in our drug research. Last week marked one of the most exciting accomplishments for our company. As many of you read in [...]

    Read Full Post »

     

    Next »

     
    Quick Nav
    Nyloxin // Chronic Pain Relief
    Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
     

     

     
    Recent News
     
    March 14, 2017
    Nutra Pharma CEO Rik Deitsch Interviewed by Stockguru.com


    February 22, 2017
    Global Small Caps Initiates Coverage on Nutra Pharma


    February 15, 2017
    Nutra Pharma and Nyloxin Featured on NBC News-Miami


     
     
     
    Announcements
    Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
     
     
    Facebook   Twitter
     
    NPC
    Privacy Policy Code of Ethics